Heparin in sepsis: current clinical findings and possible mechanisms
- PMID: 39712008
- PMCID: PMC11659142
- DOI: 10.3389/fimmu.2024.1495260
Heparin in sepsis: current clinical findings and possible mechanisms
Abstract
Sepsis is a clinical syndrome resulting from the interaction between coagulation, inflammation, immunity and other systems. Coagulation activation is an initial factor for sepsis to develop into multiple organ dysfunction. Therefore, anticoagulant therapy may be beneficial for sepsis patients. Heparin possesses a variety of biological activities, so it has a broad prospect in sepsis. Previous studies suggested that patients with sepsis-induced disseminated intravascular coagulation and high disease severity might be suitable for anticoagulant therapy. With the development of artificial intelligence (AI), recent studies have shown that patients with severe coagulation activation represent the targeted patients for anticoagulant therapy in sepsis. However, it remains necessary to accurately define the relevant biomarkers indicative of this phenotype and validate their clinical utility by large randomized controlled trials (RCTs). Analyses of data from early small RCTs, subgroup analyses of large RCTs and meta-analyses have collectively suggested that anticoagulant therapy, particularly the use of heparin, may be an effective approach for managing sepsis patients. Concurrently, debate persists regarding the optimal selection of anticoagulants, proper timing, usage and dosage of administration that should be employed to assess treatment efficacy. The primary mechanisms of heparin are acting on heparan sulfate, histones, high mobility group box 1 and heparin-binding protein, which interfere with the regulation of inflammation, vascular permeability, coagulation, endothelial function and other biological activities. However, the underlying pathophysiological processes mediating the potential therapeutic effects of heparin in the context of sepsis remain incompletely understood and warrant additional rigorous investigation to establish the mechanism more conclusively.
Keywords: anticoagulant; coagulation; heparin; mechanism; sepsis.
Copyright © 2024 Yu, Chi, Ma and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials.J Thromb Haemost. 2016 Mar;14(3):518-30. doi: 10.1111/jth.13230. Epub 2016 Feb 1. J Thromb Haemost. 2016. PMID: 26670422 Review.
-
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):8S-28S. doi: 10.1177/1076029618806424. Epub 2018 Oct 8. Clin Appl Thromb Hemost. 2018. PMID: 30296833 Free PMC article.
-
Heparins May Not Be the Optimal Anticoagulants for Sepsis and Sepsis-Associated Disseminated Intravascular Coagulation.Semin Thromb Hemost. 2024 Oct;50(7):1012-1018. doi: 10.1055/s-0044-1786754. Epub 2024 May 11. Semin Thromb Hemost. 2024. PMID: 38733977 Review.
-
Effects of anticoagulant strategies on activation of inflammation and coagulation.Expert Opin Biol Ther. 2007 Jun;7(6):855-70. doi: 10.1517/14712598.7.6.855. Expert Opin Biol Ther. 2007. PMID: 17555371 Review.
-
The role of heparin and allied compounds in the treatment of sepsis.Thromb Haemost. 2007 Sep;98(3):579-86. Thromb Haemost. 2007. PMID: 17849046 Review.
Cited by
-
Unfractionated heparin may improve near-term survival in patients admitted to the ICU with sepsis attributed to pneumonia: an observational study using the MIMIC-IV database.Front Pharmacol. 2025 Feb 27;16:1518716. doi: 10.3389/fphar.2025.1518716. eCollection 2025. Front Pharmacol. 2025. PMID: 40083381 Free PMC article.
-
A machine learning model for robust prediction of sepsis-induced coagulopathy in critically ill patients with sepsis.Front Cell Infect Microbiol. 2025 Jun 6;15:1579558. doi: 10.3389/fcimb.2025.1579558. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40546281 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical